Asset Publisher

Draft Medical Policies

Draft provider-administered drug policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.

Comment on Draft Medical Policies

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies.

We accept comments for 45 days from the posting date listed on the draft policy.

Make sure your voice is heard by providing feedback directly to us:
 

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-0878

Draft Policies

Policy # Policy Title Print View
MP-081 Allergy Immunotherapy
MP-527 Bio-Engineered Skin and Soft Tissue Substitutes
MP-597 Amniotic Membrane and Amniotic Fluid
MP-758 Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis